FDA feedback supports late-stage amsulostat trial; SNT-4728 shows significant anti-inflammatory effect in Parkinson's-related brain regions. Cash runway extended into Q3 2027 after $8.8M capital raise, with multiple clinical catalysts expected in H2 2026.

Original document:

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.